All articles tagged with #mrna
A mouse study demonstrates that an experimental mRNA treatment can rejuvenate immune cells, specifically T cells, potentially improving immune response in aging, but further research is needed to assess its applicability in humans.
A Stanford study highlights a rare risk of myocarditis, or heart inflammation, associated with mRNA Covid-19 vaccines, especially in young men and children, with an estimated occurrence of 1 in 140,000 after the first dose and 1 in 32,000 after the second. While most recover quickly, the study emphasizes that Covid itself is more likely to cause myocarditis than the vaccine, and advises seeking medical help if chest pains occur post-vaccination.
MIT researchers have identified potential new targets for a tuberculosis vaccine by screening bacterial proteins and testing immune responses, aiming to develop a more effective vaccine than the current BCG, with promising results from mRNA vaccine experiments in human cells.
The article discusses the revolutionary potential of mRNA technology for treating cancer, genetic diseases, and autoimmune conditions, highlighting how US federal policies are currently hindering its development and application, risking a setback in biomedical innovation and international competitiveness.
Research shows that COVID-19 mRNA vaccines can enhance the effectiveness of cancer immunotherapy by 'warming up' cold tumors, significantly improving survival rates in lung and skin cancer patients, potentially leading to a new approach in cancer treatment.
A study finds that COVID-19 mRNA vaccines, like Pfizer and Moderna, can boost the immune system to recognize and kill cancer cells, especially when combined with immunotherapy, potentially extending benefits to more cancer patients. The vaccines act as an immune alarm, helping to turn 'cold' tumors 'hot,' and are being tested in clinical trials for lung cancer.
Preliminary research suggests that Pfizer and Moderna mRNA COVID-19 vaccines may enhance immune responses in some cancer patients undergoing immunotherapy, potentially improving survival rates, especially in lung and skin cancers, by acting as immune system stimulants beyond their role in fighting COVID-19.
Research suggests that cancer patients with advanced lung or skin cancer who received a COVID-19 mRNA vaccine within 100 days of starting immunotherapy lived significantly longer, potentially paving the way for a universal cancer vaccine, though further clinical trials are needed to confirm these findings.
A study suggests that mRNA Covid vaccines from Pfizer-BioNTech or Moderna may enhance the effectiveness of cancer immunotherapy, with vaccinated patients living longer than unvaccinated ones, possibly due to immune system alerting. This benefit is in addition to Covid protection, especially important for immunocompromised cancer patients.
Researchers at the University of Florida have developed a promising universal cancer vaccine using mRNA technology that stimulates the immune system to attack various tumors, especially when combined with immune checkpoint inhibitors, showing strong results in mice and paving the way for future human trials.
The article discusses the rise of mRNA technology from obscurity to a Nobel-winning breakthrough during the COVID-19 pandemic, its potential for future medical advances, and recent political and financial challenges that threaten its development, including government cancellations and political opposition.
Scientists have developed a universal antiviral treatment using a rare immune mutation, potentially serving as biological PPE for future pandemics by providing immunity against unknown viruses, with successful tests in animals and plans for human trials.
A study from the University of Florida demonstrates that an experimental mRNA vaccine can boost immune responses against tumors in mice, potentially leading to a universal cancer vaccine that works broadly across different cancer types and in combination with existing immunotherapies. The vaccine stimulates the immune system not by targeting specific tumor proteins but by activating immune responses similar to fighting a virus, showing promising results in eliminating tumors in mouse models. Researchers aim to advance this technology to human trials, with the hope of providing a new, broadly applicable cancer treatment.
The US Department of Health and Human Services is significantly reducing funding for mRNA vaccine research, canceling nearly $500 million in contracts, but is still supporting mRNA therapies for cancer and genetic conditions, indicating a shift in focus from vaccines to other medical applications.
Researchers at IBM and Moderna used a quantum computer to simulate the secondary structure of a 60-nucleotide-long mRNA sequence, the longest ever achieved with quantum simulation, demonstrating potential for more accurate vaccine development and overcoming limitations of classical and AI methods.